The ISH Council would like to acknowledge the assistance of the following Corporate Members who are participating in the ISH and therefore helping to promote the advancement of scientific research and knowledge in hypertension and associated cardiovascular diseases.
Current Corporate Member
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 16,000 employees worldwide.
The organization is committed to becoming a global category leader in Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience, DM Complications and Metabolic Diseases.
Astellas has a number of key strengths in the Japanese market: one of the largest teams of quality MRs with high-level detailing skills; a rich lineup of products, both in terms of therapeutic areas and numbers of products; and solid promotional and support system capable of marketing numerous products at the same time. Astellas can also point to several successful marketing alliances for major products including a treatment for hypertension. For more information on Astellas Pharma Inc.
For more information please visit astellas.com/en
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees.
Boehringer Ingelheim’s products have long been highly successful in the treatment of respiratory, cardiovascular, central nervous system, urological and viral disorders. In addition, the company has successfully advanced its research in thrombo-embolic, cardio-metabolic and oncological diseases.
Boehringer Ingelheim has research and development (R&D) facilities at 12 sites in seven countries and production plants in 15 countries. In 2009, the company spent 21% of net sales in its largest business segment Prescription Medicines on research and development.
The objectives and beliefs of Boehringer Ingelheim can be summed up in a single phrase: Value through Innovation. This vision has helped the company to build on its strengths and make the most of its distinctive character. In a competitive and fast-changing world, the value of products, services and companies is constantly changing. Real customer value today can only be created by constantly developing new solutions and doing what we already do better.
In 2010, the world's largest family-owned pharmaceutical company celebrated its 125th anniversary. Boehringer Ingelheim has always stayed true to the values of the company's founder, Albert Boehringer, and in its jubilee year also confirmed its commitment to its guiding principle "Value through Innovation".
For more information please visit boehringer-ingelheim.com
Boryung Pharmaceutical Company
Boryung Pharmaceutical Company has continually invested heavily in research and development and made efforts to produce high-quality products to contribute what it can to liberate people from debilitating pain and diseases.
Products such as our Gelfos M, Yongkaksan and Kyushin have been much loved by our customers so much that our company has emerged as the most familiar and trusted household brand in Korea.
In many nations around the world, including Korea, the birthrate is declining steadily while the median age of the population is increasing. This has resulted in an increased occurrence of geriatric diseases afflicting an aging population, an issue that needs to be addressed. And as quality of life is becoming increasingly important, interest in health and well being is also rising.
In line with these trends Boryung Pharmaceutical Company has concentrated on developing new drugs and capitalized on advanced manufacturing and marketing techniques to continuously offer medicines that will enhance the quality of life for everyone. To this end Boryung has been intensively engaged in innovative research and development to seek out new solutions to meet our customers’ present and future needs.
Boryung Pharmaceutical Company promises once again that we will constantly prepare for the future, and continue to grow to be a major contributor to the health of humanity throughout the world.
For more information please visit www.boryung.co.kr
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain.
For more information, please visit: daiichisankyo.com.